Wednesday, July 14, AstraZeneca (AZ) announced that the UK’s Competition and Markets Authority (CMA) has cleared the Alexion buyout without raising any antitrust concerns.
The go-ahead follows blessings from competition authorities in the US and EU and marks the final regulatory approval the company needs to seal the deal, which is now expected to close July 21.
The transaction, unveiled in December, gives AZ additional know-how in immunology and a presence in rare diseases.
The combination of Alexion offers an immediate boost to AZ’s top line thanks mainly to complement inhibitors Soliris and Ultomiris, which together brought in US$1.37 billion in first-quarter sales. AZ also sees broad application of Alexion’s complement platform and other immunology technologies in various therapeutic areas—including oncology—to fuel future growth.
Once the takeover completes, AZ is creating a rare disease unit bearing Alexion’s name with headquarters at the US firm’s current location in Boston. The franchise will be led by Marc Dunoyer, currently AZ’s chief financial officer, who will also take on the title of chief strategy officer. His CFO role will be filled by Alexion’s CFO, Aradhana Sarin.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI